Quick Summary:
The global Fibromyalgia Therapeutics market is on an upward trajectory, and this comprehensive report gives a clear view of the landscape, key players, and trends shaping its future. Recognized as a robust and promising sector, it is estimated to expand from a market size of US$3 Billion in 2022 to US$3.8 Billion by 2030. Market leaders such as Allergan plc, Boehringer Ingelheim GmbH, and Pfizer Inc., among others, are all profiled within the report.
The U.S. and China, two of the largest global economies, play a significant role in the market's expansion. Europe and Asia-Pacific regions also witness steady growth rates, offering more potential avenues for business. Our customized, in-depth analysis will equip you with the knowledge to make strategic decisions and take advantage of upcoming opportunities. With special features, including access to an interactive peer-to-peer collaborative platform and complimentary updates for one year, this report is your essential guide to navigating the future of the Fibromyalgia Therapeutics market.
Global Fibromyalgia Therapeutics Market to Reach $3.8 Billion by 2030
The global market for Fibromyalgia Therapeutics estimated at US$3 Billion in the year 2022, is projected to reach a revised size of US$3.8 Billion by 2030, growing at a CAGR of 3% over the analysis period 2022-2030. Antiepileptics, one of the segments analyzed in the report, is projected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antidepressants segment is readjusted to a revised 3.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $809.6 Million, While China is Forecast to Grow at 5% CAGR
The Fibromyalgia Therapeutics market in the U.S. is estimated at US$809.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$736.2 Million by the year 2030 trailing a CAGR of 5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 2.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$485.6 Million by the year 2030.Select Competitors (Total 22 Featured) -
- Allergan plc
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Innovative Med Concepts Inc.
- Pfizer Inc.
- SWITCHBIOTECH LLC
- Zynerba Pharmaceuticals Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Fibromyalgia Therapeutics
What is the estimated value of the Global Market for Fibromyalgia Therapeutics?
The Global Market for Fibromyalgia Therapeutics was estimated to be valued at $3 Billion in 2022.
What is the growth rate of the Global Market for Fibromyalgia Therapeutics?
The growth rate of the Global Market for Fibromyalgia Therapeutics is 3.0%, with an estimated value of $3.8 Billion by 2030.
What is the forecasted size of the Global Market for Fibromyalgia Therapeutics?
The Global Market for Fibromyalgia Therapeutics is estimated to be worth $3.8 Billion by 2030.
Who are the key companies in the Global Market for Fibromyalgia Therapeutics?
Key companies in the Global Market for Fibromyalgia Therapeutics include Allergan plc, Boehringer Ingelheim GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company, Innovative Med Concepts Inc., Pfizer Inc., SWITCHBIOTECH LLC and Zynerba Pharmaceuticals Inc..
| Report Attribute | Details |
|---|---|
| No. of Pages | 263 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 3 Billion |
| Forecasted Market Value ( USD | $ 3.8 Billion |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Fibromyalgia Syndrome: A Prelude
- Recent Market Activity
- Fibromyalgia Therapeutics Market: A Nascent Sector
- A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
- FDA Approved Fibromyalgia Drugs
- IMC-1: A Revolutionary Combination Therapy
- Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica
- Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
- Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
- Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
- Fibromyalgia Treatment through High-Pressure Oxygen Application
- EU approves New Device to Treat Fibromyalgia and Migraine
- Fibromyalgia Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
- Allergan plc (Ireland)
- Boehringer Ingelheim GmbH (Germany)
- Daiichi Sankyo Company Limited (Japan)
- Eli Lilly and Company (USA)
- Innovative Med Concepts, Inc. (USA)
- Pfizer, Inc. (USA)
- Pierre Fabre Médicament (France)
- SWITCHBIOTECH LLC (USA)
- Zynerba Pharmaceuticals, Inc. (USA)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Fibromyalgia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 14: USA Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 15: USA Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 16: USA 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
CANADA
- Table 17: Canada Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 18: Canada Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 19: Canada 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
JAPAN
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 20: Japan Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 21: Japan Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 22: Japan 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
CHINA
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 23: China Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: China Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 25: China 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
EUROPE
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 26: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 27: Europe Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 28: Europe 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 29: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: Europe 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
FRANCE
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 32: France Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: France Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: France 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
GERMANY
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 35: Germany Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Germany Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Germany 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
ITALY
- Table 38: Italy Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Italy Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Italy 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 41: UK Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: UK Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: UK 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
SPAIN
- Table 44: Spain Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Spain Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: Spain 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
RUSSIA
- Table 47: Russia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Russia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: Russia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 50: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Rest of Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: Rest of Europe 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
AUSTRALIA
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- Table 59: Australia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Australia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: Australia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
INDIA
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- Table 62: India Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: India Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: India 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
SOUTH KOREA
- Table 65: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: South Korea Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: South Korea 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
REST OF ASIA-PACIFIC
- Table 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Rest of Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Rest of Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
LATIN AMERICA
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- Table 71: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 72: Latin America Historic Review for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
- Table 74: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
ARGENTINA
- Table 77: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Argentina Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: Argentina 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
BRAZIL
- Table 80: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Brazil Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: Brazil 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
MEXICO
- Table 83: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Mexico Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: Mexico 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
REST OF LATIN AMERICA
- Table 86: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Rest of Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
MIDDLE EAST
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- Table 89: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 90: Middle East Historic Review for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
- Table 92: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
IRAN
- Table 95: Iran Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Iran Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Iran 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
ISRAEL
- Table 98: Israel Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Israel Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Israel 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
SAUDI ARABIA
- Table 101: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Saudi Arabia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Saudi Arabia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
UNITED ARAB EMIRATES
- Table 104: UAE Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: UAE Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: UAE 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
REST OF MIDDLE EAST
- Table 107: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Rest of Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 109: Rest of Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
AFRICA
- Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
- Table 110: Africa Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Africa Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 112: Africa 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
Companies Mentioned
A selection of companies mentioned in this report includes:
- Allergan plc
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Innovative Med Concepts Inc.
- Pfizer Inc.
- SWITCHBIOTECH LLC
- Zynerba Pharmaceuticals Inc.
